ArticleLe Mali medical2025
[Evaluation Of Dosage Errors During Mass Treatment Campaigns Targeting Lymphatic Filariasis And Onchocerciasis In The Health Districts Of Bougouni And Kolondièba, Mali].
Article in Le Mali medical, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to assess dosing errors when administering ivermectin (IVM) according to height, using a measuring cup with reference to the manufacturer's recommended dosage according to weight. For this purpose, a secondary analysis of the database of a community trial conducted in the health districts of Bougouni and Kolondièba was carried out. This made it possible to assess the proportions of participants who received underestimated doses, and to identify the factors associated with underestimation of IVM dose when using the toise. In all, 8.6% of participants (258/3011) received an underestimated dose. Of these, the most represented age group was the under-10s, with 63.18% (163/258), and the over-20s, with 25.19% (65/258). There was a significant correlation between missing dose quantities and height (r=17.1%, p=0.00593), as well as age (r=14.2%, p=0.02227). Participants under 10 years of age were 2.62 times (OR= 2.62; 95% CI: 1.58 - 4.43) more likely to be under-dosed than those aged 10 and over. Having a height of 120 cm or more made a participant 22.5 times (OR= 22.5; 95% CI: 13.5 - 38.4) more likely to be underdosed compared to those with a height ranging from 90 to 119 cm. These results suggest that it is crucial to make adequate adjustments to ensure a favorable response in CT participants in areas receiving MVI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.